• EVOCAL Health

EVOCAL Health Releases Cloud-Based Vocal Biomarker Development Platform

Software-as-a-Service (SaaS) Platform To Leverage the Potential Of The Human Voice As A Biomarker For Health


Hamburg/Boston (USA), September 28, 2021: EVOCAL Health, a biopharmaceutical digital health company unlocking the human voice as a biomarker for AI-based detection and treatment of diseases (so-called vocal biomarkers), today announced the release of the company’s cloud-based Vocal Biomarker development platform.


EVOCAL Health has developed a device-agnostic platform that enables to collect, monitor, and analyze voice data seeking a multitude of features within the human voice, that are directly correlated to cardiovascular, respiratory, neurodegenerative, and mental diseases. The technology runs on a device-agnostic and cloud-based solution for clinical trials and remote monitoring designed to deliver objective, unbiased data about a patient's disease progression and his or her response to a certain treatment or drug.


The Software-as-a-Service (SaaS) platform complies with the highest GDPR standards and can be leveraged by study sponsors around the globe to non-invasively gain a better understanding of a patient’s disease progression and his/her response to a certain treatment or drug - using only the human voice and a smartphone to better achieve study objectives using real-world data (RWD) and real-world evidence (RWE) during clinical trials and remote monitoring.



EVOCAL Health CEO/COO and Co-Founder Philip Mertes: “Today, voice technology is considered as one of the most promising sectors, with healthcare being predicted to be a dominant vertical in voice applications. EVOCAL Health's core technology now runs on a cloud-based and device-agnostic platform. The technology can be integrated via API/SDK into any existing application and/or devices to generate further RWD and RWE evidence in clinical trials. The scalable platform technology is designed to deliver objective, unbiased data about a patient's disease progression and his or her response to a certain treatment or drug.”

The SaaS platform complies with the highest GDPR and compliance standards and is leveraged by study sponsors around the globe to improve remote monitoring and patient engagement during clinical trials. Achieve your study objectives using RWD, validated algorithms, and expert data analysis from the scientists at EVOCAL Health.


“From the very beginning, we believed that innovating healthcare with patient-centric solutions in the 21st century is all about building synergetic partnerships: That’s why we have developed a scalable platform technology that enables us now to develop customized biomarkers with and for our clients that help diagnose, monitor and predict health conditions across a number of disease areas: independently and in partnership with leading life sciences companies around the world,” said Dirk Simon, CEO and Co-Founder of EVOCAL Health.